▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #292 by analyst upside · 2026-11-12
CMPX
Compass Therapeutics, Inc.
Healthcare · Market Cap $150M · P/E 0x
ANALYST PRICE TARGET
+534.0%
implied upside to consensus target
Current Price $0.83
Consensus Target $5.26
Bull Target $12.0
Bear Target $0.9
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
7
Hold
2
Sell
1
52-Week Low $0.67
52-Week High $6.88
YTD Return -83.9%
FUNDAMENTALS
Market Cap $150M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.46
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.67
52-Week High $6.88
Current Price $0.83
Bear Target $0.9
Bull Target $12.0
● Now $0.83 ● Target $5.26
TRADING DATA
Avg Volume 4.0M
YTD Return -83.9%
Analyst Count 11
Consensus Buy
Upside to Target +534.0%
Last Updated 2026-11-12

ANALYST SUMMARY

Compass Therapeutics, Inc. (CMPX) is currently trading at $0.83 with a Wall Street consensus price target of $5.26, implying potential upside of 534.0% over the next 12 months. 11 analysts currently cover CMPX, with a consensus rating of Buy - 73% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $12.0, while the most cautious has a target of $0.9.

CMPX operates in the Healthcare sector with a market capitalisation of $150M. The stock is down 83.9% year-to-date and is currently trading near the lower end of its 52-week range of $0.67 – $6.88.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CMPX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Craig-Hallum - Reiterated
Buy → Buy 2026-09-23 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-09-23 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-09-23 62% win rate (8 calls)
Wedbush ↓ Downgrade
Outperform → Neutral 2026-09-23 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-09-23 31% win rate (48 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-08-07 14% win rate (7 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-04-28 Building track record
Citizens reit
Market Outperform → Market Outperform 2026-04-28 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
33
out of 100
Coverage depth
19/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →